The Board of Directors of the Company at its meeting held today i.e. Wednesday, August 13, 2025 at Registered Office of the Company has inter-alia has considered and approved the Un-audited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivanza Biosciences reported a sharp jump in Q1 FY26 standalone revenue from operations at Rs. 782.06 lakhs, up from Rs. 42.78 lakhs in Q1 FY25 — a roughly 18x year-on-year increase driven mainly by stock-in-trade purchases of Rs. 770.95 lakhs, suggesting a trading-led quarter. However, profit after tax shrank to just Rs. 1.86 lakhs from Rs. 22.65 lakhs a year ago, as the thin trading margin was eaten up by employee, finance and other costs. The full-year FY25 had ended in a loss of Rs. 69.51 lakhs on Rs. 294.28 lakhs of revenue. On a consolidated basis (including Vivanza Lifesciences Pvt Ltd), revenue surged to Rs. 893.92 lakhs with a PAT of Rs. 8.70 lakhs. The limited review report from Shivam Soni & Co is clean, with no qualifications or observations.
The headline revenue growth is striking but low quality — it comes with razor-thin margins and negligible bottom line, so shareholders should not read this as a fundamental earnings turnaround. The stock is likely to react to the revenue scale-up but underlying profitability remains very weak.